Receptor heteromerization has the potential to alter every facet of receptor functioning, leading to new pharmacological profiles with increased signaling diversity and regulation from that of the monomeric receptor, or indeed receptor homomer. An understanding of the molecular consequences of receptor heteromerization will provide new insights into the physiology and pathology mediated by receptors, expanding the possibilities for pharmacological discovery. Particularly advantageous approaches to investigate novel heteromer pharmacology utilize cell-based assay technologies that assess ligand-dependent functional responses specific to the receptor heteromer. Importantly, this allows for differentiation of heteromer-specific pharmacology from pharmacology associated with the co-expressed receptor monomers and homomers. The Receptor-Heteromer Investigation Technology (Receptor-HIT) successfully employs a proximity-based reporter system, such as bioluminescence resonance energy transfer (BRET), in a configuration that enables differentiation of such heteromer-specific pharmacology. Therefore, Receptor-HIT provides a simple, robust and versatile approach for investigating the elusive “biochemical fingerprint” of receptor heteromers.

Keywords: Receptor-HIT, GPCR-HIT, GPCR, RTK, heteromer, BRET, bioluminescence resonance energy transfer
robustly differentiate heteromer-specific pharmacology from that of the component receptors.

**RECEPTOR-HETEROMER INVESTIGATION TECHNOLOGY**

A novel technique recently developed to enable identification and pharmacological profiling of heteromers is the Receptor-Heteromer Investigation Technology (Receptor-HIT). This provides information on ligand-dependent functional responses specific to the heteromer. Receptor-HIT uses a proximity-based reporter system comprising four elements, three of which are: labeled Receptor A, untagged Receptor B, and a labeled interacting Protein C that is recruited to the heteromer in a ligand-dependent manner (See et al., 2011). This configuration is illustrated in Figure 1 using bioluminescence resonance energy transfer (BRET), however, the approach can be applied using a variety of reporter systems including fluorescence resonance energy transfer (FRET), bimolecular fluorescence complementation (BiFC), bimolecular luminescence complementation (BiLC), enzyme fragment complementation (EFC), and the protease-cleaved transcription factor assay system known as Tango™ (Mustafa et al., 2010; Mustafa and Pfleger, 2011). Co-expression of the aforementioned elements in cells enables the signal between the label of choice on Receptor A and complementary label on Protein C to be monitored. The fourth element in the system is a ligand that, upon binding to untagged Receptor B or the heteromer, selectively modulates the recruitment of Protein C to Receptor B and/or the heteromer (See et al., 2011; Mustafa et al., 2012). Receptor-HIT is unsuitable for investigating homomers due to this receptor-selectivity requirement, but heteromers of closely related receptor subtypes where a selective agonist may be unavailable can still be assessed. This issue is overcome by additional use of an antagonist selective for Receptor A, thereby meaning that Receptor B

![Figure 1](image-url)
and/or the heteromer are still activated selectively. Alternatively, it is possible to use a non-selective ligand if it does not modulate recruitment of Protein C to Receptor A in the absence of Receptor B (Porrello et al., 2011). Whichever approach is used, generation of a signal upon application of the ligand indicates that Protein C has been recruited to the heteromer, thereby bringing the label on Receptor A into close proximity with the label on Protein C. The signal obtained is not only indicative of the receptors being in a heteromeric complex, it also reveals an aspect of the heteromer's pharmacology through generation of ligand-dependent functional responses.

Receptor-HIT is an excellent assay for identifying and profiling heteromers as signals do not result from the homomeric or monomeric receptor populations (See et al., 2011). The ligand-dependent nature of the signal also enables screening, identification, and profiling of compounds exhibiting heteromer-specific or biased signaling (Mustafa and Pfleger, 2011; Mustafa et al., 2012).

The Receptor-HIT assay has largely been published with respect to GPCRs in the form of the GPCR-Heteromer Identification Technology (GPCR-HIT; Ajoudi and Pfleger, 2010; Mustafa et al., 2009, 2011, 2012; Mustafa and Pfleger, 2011; Porrello et al., 2011; See et al., 2011), however it can also be applied to other receptors, including RTKs (Pfleger, 2011; Story et al., 2011), ionotropic receptors and steroid receptors. Consequently, there is also an extensive number of interacting partners that can be used. For example, GPCR-HIT studies can utilize G proteins or β-arrestins, whereas we have found Gβ2 to be particularly amenable to Receptor-HIT assays investigating RTKs (Pfleger, 2011; Story et al., 2011).

BRET is our preferred platform for Receptor-HIT (Figure 1) because it can monitor protein proximity in live cells in real time at 37°C without the need for cell lysis, the assay does not rely upon proteins refolding in a complementation event to produce a read-out, and no alteration of receptor function is required (Mustafa et al., 2010). The traditional configuration for studying receptor heteromers using BRET involves tagging one receptor with the RLuc enzyme, while the second receptor is tagged with the acceptor fluorophore. A particular limitation to this approach is that overcrowding of receptors in the endoplasmic reticulum or degenerative compartments can lead to non-specific “bystander BRET” (Pfleger and Eidne, 2006). This is commonly addressed by employing BRET saturation assays (Mecerreyes et al., 2002), however these are rather laborious. The ligand dependency of Receptor-HIT addresses this issue as it requires Receptor B or the heteromer to be capable of binding ligand (Figure 1), either because it is sufficiently mature and/or because it is appropriately localized to provide the ligand access for binding. Furthermore, although providing evidence of proximity of the two receptors, no functional information about the heteromer is revealed by saturation assays (Mustafa et al., 2012). In contrast, the use of an interacting protein also enables functional responses to be assessed, with the potential to uncover novel heteromer-specific pharmacology (Mustafa et al., 2012).

While there are advantages to using BRET as outlined above, there are also advantages to using other platforms in certain situations. For example, although FRET is not a real-time assay and requires cell lysis for signal detection, it is probably capable of achieving higher levels of screening throughput than BRET. Furthermore, assay systems like FRET and BiFC are more amenable to assessing subcellular localization if combined with confocal microscopy. However, because FRET uses a fluorophore as donor, there are issues arising from the need for external excitation. These include autofluorescence, photobleaching, cell damage, and direct acceptor excitation. Some of these issues can be addressed using time-resolved FRET (TR-FRET; Cottet et al., 2012). BiFC enables specific visualization of complemented fluorophores, and therefore the fused proteins of interest, but this is not a real-time assay due to a time delay while refolding occurs and once complemented, the proteins remain associated (Porrello et al., 2011). BRET is very sensitive to distance and relative donor–acceptor orientation. This is advantageous in terms of proximity specificity, however, it means that receptors could potentially form a heteromer without this being detected by BRET, and a lack of signal should be interpreted with caution (Pfleger et al., 2006). Other platforms may have a lower false-negative rate than BRET, however, the potential for higher false-positives may then need to be considered.

APPLICATION OF RECEPTOR-HIT USING BRET

Receptor-HIT has been used effectively on the BRET platform to investigate multiple established and novel heteromers. The CCR2:CCR5 and CCR2-CXCR4 heteromers that have been described by a number of studies (Mellado et al., 2001; Rodriguez-Grade et al., 2004; El-Asmar et al., 2005; Percherancier et al., 2005; Springael et al., 2006; Sohy et al., 2007, 2009) have recently been profiled in terms of dose-response curves, kinetics and Z′ data using GPCR-HIT (See et al., 2011). Of particular note were the findings with the combination of CXCR4/RLuc, β-arrestin2/Venus and CCR2. Treatment with CXCL12 (CXCR4 agonist) resulted in a relatively transient BRET signal that returned to baseline before 40 min, whereas addition of CCL2 (CCR2 agonist) resulted in a more prolonged BRET kinetic profile, indicative of CCR2 forming a complex with CXCR4. Intriguingly, treatment with a combination of CXCL12 and CCL2 resulted in a prolonged and substantially higher BRET signal than observed with either agonist alone. Possible explanations for this include β-arrestin2 recruitment being facilitated by both types of receptor complex being in active receptor conformations, or proximity of the donor and acceptor being sufficiently close to enable detection of changes in donor–acceptor distance and/or relative orientation. Either way, this observation provides good evidence for specific reporting of β-arrestin2 recruitment to the heteromer complex (See et al., 2011).

When generating dose–response curves with Receptor-HIT data, the Hill slope has been seen to alter for particular combinations depending upon whether the tagged or untagged receptor is activated, consistent with stabilization of distinct complex conformations with the different ligands. For example, with the CCR5/RLuc, β-arrestin2/Venus and CCR2 combination, the dose–response curve with CCL2 was significantly steeper than with CXCL4 (CCR5 agonist; See et al., 2011). As discussed previously, the reason for this difference is currently unclear, however, as the protein expression profile is identical in both cases and the only difference is the agonist treatment, this observation may help to shed light on the mechanism of GPCR heteromerization and/or allosterism across the complex in the future (See et al., 2011).
Receptor-HIT (in the form of GPCR-HIT) has also been used to investigate the heteromer between the angiotensin II (AngII) type 1 receptor (AT1R) and the AngII type 2 receptor (AT2R; Porrello et al., 2011). A number of studies have shown that the AT2R does not couple to arrestins and does not internalize following treatment with AngII (Pucell et al., 1991; Huynh et al., 1994; Turu et al., 2006). Our BRET data indicating a lack of β-arrestin2/Rluc8 recruitment to AT2R/Venus are also consistent with these findings (Porrello et al., 2011). Therefore, upon co-expression of untagged AT2R with β-arrestin2/Rluc8 and AT1R/Venus, even though AngII can bind to both receptors, the ligand is still selective in terms of recruiting β-arrestin2 to only the untagged receptor. Therefore, the observation that a ligand-induced BRET signal results upon addition of AngII is indicative of AT1R-AT2R heteromerization (Porrello et al., 2011).

Receptor-HIT on the BRET platform has recently been used to characterize the novel heteromer between the α1A-adrenoceptor (α1AAR) and the CXC chemokine receptor 2 (CXCR2) that may play a role in prostate stroma (Mustafa et al., 2012). The Receptor-HIT studies showed that the heteromer recruits β-arrestin2 in a norepinephrine (NE)-dependent manner that can be blocked by both the α1AR antagonist Terazosin and the CXCR2-specific allosteric inverse agonist SB265610 (Figure 2).

This is despite the very weak β-arrestin2 interaction with α1AAR monomers/homomers in transfected human embryonic kidney 293 cells (Mustafa et al., 2008), but consistent with the observation of α1AAR recruiting β-arrestin2 in prostate stroma (Hennenberg et al., 2011). The specificity of this change in α1AAR pharmacology with co-expression of CXCR2 was demonstrated by the lack of effect upon co-expression of CC chemokine receptor 2, vasopressin receptor 2 (V2R), or orexin receptor 1 (Mustafa et al., 2012).

The ligand-dependent nature of Receptor-HIT enables it to report on, albeit without differentiating between, constitutive and dynamic heteromers (Mustafa and Pfleger, 2011). The α1AAR-CXCR2 complex is an example of a constitutive heteromer that exhibits novel pharmacology revealed by the ligand dependency of Receptor-HIT (Mustafa et al., 2012). Indeed, BRET

![FIGURE 2](image-url)
REFERENCES

Ayoub, M. A., and Pfleger, K. D. G. (2010). Recent advances in bioluminescence resonance energy transfer technologies to study GPCR heteromerization. Curr. Opin. Pharmacol. 10, 44–52. 1AAR pharmacology revealed by GPCR-HIT was only observed with CXCR2 and not with V2R. This indicates that proximity between GPCRs does not necessarily result in a functional effect of one receptor on another, and further demonstrates the ability of Receptor-HIT to unmask specific heteromer functionality (Mustafa et al., 2012).

Receptor-HIT is also able to investigate the functionality of apparent dynamic receptor interactions, even though it is unable to determine the dynamics per se. This is seen for the heteromer between the glucagon-like peptide-1 receptor (GLP-1R) and the gastric inhibitory polypeptide receptor (GIPR; Schelhorn et al., 2012). Using the combination of GLP-1R-Rluc and YPet-β-arrestin2 in the absence and presence of GIPR, dose–response data were generated indicating that expression of GIPR partially inhibited GLP-1-induced recruitment of YPet-β-arrestin2 proximal to GLP-1R-Rluc. This inhibition was overcome by co-treatment with GIPR (Schelhorn et al., 2012). The authors of this study suggested a model to explain their GPCR-HIT data, whereby formation of the heteromer occurs as a consequence of low affinity binding of GLP-1 to the GIPR in addition to the GLP-1R. The heteromer is proposed to recruit β-arrestin2 less well in comparison with the GLP-1R monomer/homomer. Co-treatment with GIP is therefore suggested to compete off the GLP-1 from GIPR, resulting in the heteromer being dissolved and allowing improved GLP-1-induced recruitment of β-arrestin2 to GLP-1R (Schelhorn et al., 2012).

Receptor heteromers are complexes with unique pharmacology that are likely to be expressed in a distinct tissue-specific manner. This makes them exciting new prospects as drug targets, with the goal of developing drugs with improved selectivity and reduced side effects. Indeed, the concept of biased signaling is now well established and applies as readily to receptor heteromers as it does to monomers/homomers (Mustafa et al., 2010). Therefore, heteromerization provides enormous opportunities for identifying ligands with heteromer-selective and/or heteromer-biased pharmacology, such as that observed with Labetalol acting at the 1AAR-CXCR2 heteromer (Mustafa et al., 2012).

Screening is an essential step in the identification of lead compounds, and consequently there is a need to develop heteromer assays that are compatible with this process. An assay’s suitability for screening can be gauged by its Z’ value; Z’ values > 0.5 indicate assays that are highly suitable (Zhang et al., 1999). The potential of Receptor-HIT as a screening assay has been demonstrated with the CCR2-CXCR5 and CCR2-CXCR4 chemokine receptor heteromers for which a Z’ value of 0.68 was generated with both combinations (See et al., 2011). The Z’ value for the 1AAR-CXCR2 heteromer (Mustafa et al., 2012) was 0.87 (See and Pfleger, unpublished observations). Unlike profiling, screening with Receptor-HIT is a two-step process. Using BRET for example, compounds are first screened with the Receptor-HIT configuration of Receptor A-Rluc, Receptor B and Protein C-YFP (Figure 1). This may generate hits for ligands that bind to Receptor A, Receptor B (when in a heteromer) or the heteromer specifically. These hits are then re-screened in parallel with the configurations Receptor A-Rluc with Protein C-YFP, and Receptor B-Rluc with Protein C-YFP. This will then enable differentiation between ligands that bind to Receptor A directly, ligands that bind to Receptor B directly, and those that are heteromer-selective (revealed by a lack of signal in the latter two assay configurations). Furthermore, the generation of dose–response curves for the different configurations can enable shifts in potency as well as efficacy to be evaluated. Comparison of different screening pathways can also reveal compounds exhibiting biased signaling as a consequence of heteromerization (Mustafa et al., 2012).

Finally, the amenability of Receptor-HIT for identifying heteromers or profiling/screening compounds is dependent upon the existence of a suitable “Protein C” for a particular receptor-receptor combination (Figure 1). For example, β-arrestin2 is a particularly good interacting partner for most GPCRs, and when it is not, G protein can often be utilized instead. It is also important not to make assumptions in terms of Protein C selection, as heteromerization can change the pharmacological profile in a manner that changes interactions with Protein C. This is illustrated by the findings with the 1AAR and the distinct β-arrestin2 recruitment profile when forming the 1AAR-CXCR2 heteromer (Mustafa et al., 2012).

CONCLUDING REMARKS

The formation of receptor complexes has a significant impact on cellular signaling. Receptor heteromers are of particular interest due to the unique biochemical profile they attain through heteromerization. Characterization of a heteromer’s biochemical fingerprint in heterologous expression systems is the first step to identifying the function of the heteromer in native tissue. Receptor-HIT is a novel cell-based approach for identifying and profiling heteromers that provides information on ligand-induced functional responses specific to the heteromer. The approach is highly versatile, allowing for simple and yet robust heteromer characterization. Utilizing a platform such as BRET, Receptor-HIT is a powerful tool that enables a deeper understanding of the molecular and physiological relevance of heteromers to be revealed.

ACKNOWLEDGMENTS

Work in the authors’ laboratory using Receptor-HIT has been funded by the National Health and Medical Research Council (NHMRC) of Australia (#566736), the Australian Research Council (ARC, DP120101297) and Dimerix Bioscience Pty Ltd. Elizabeth K. M. Johnstone is funded by the Richard Walter Gibson Medical Research Scholarship from The University of Western Australia and Kevin D. G. Pfleger is an ARC Future Fellow (FT101000271).

www.frontiersin.org

August 2012 | Volume 3 | Article 101 | 5

* fendo-03-00101* — 2012/8/20 — 19:46 — page 5 — #5

Duclos, H., Wang, J., Dumancic, M. M., and Trouw, S. C. (2010). Experimental determination of the Förster distance for two commonly used bioluminescence resonance energy
transfer pairs. Annu. Clin. 82, 452–453.
El-Ammar, I., Sprigs, J.-Y., Bals, S., Vassart, G., and Parmentier, M. (2005). Evidence for negative binding cooperativity within GPCR-GPCR homo-oligomers. Mol. Pharmacol. 67, 469–469.
Ferre, S., Balae, R., Boveret, M., Caron, M. G., Dev, A. L., Dvorak, T., Fonse, K., George, S. R., Jeričk, J. A., Lobes, M. J., Mackie, K., Milligan, G., Pilger, R. D., Piz, P. J., Volle, N. D., Wahlstedt, M., Woods, A. S., and Frenz, B. (2009). Building a new conceptual framework for receptor heteromerization. Nat. Rev. Mol. Cell. Biol. 10, 151–154.
Fonse, K., Maselloni, D., Lee, G., and Agati, L. F. (2010). Molecular integration via allosteric interactions in receptor heteromers. A working hypothesis. Curr. Opin. Pharmacol. 10, 14–22.
Henningson, M., Schäfer, R., Rosson, A., Strittmatter, F., Walder, S., Wolf, C., and Grütze, C. (2011). β-arrestin-2 is expressed in human prostate tissue and mediates a binding partner of α1-adrenoceptors. World J. Surg. 39, 157–163.
Hunyady, L., Ber, B., Baló, T., and Catt, K. J. (1994). Identification of a sympathetic Site-Topoc locus that determines agonist-induced internalization of the α1B angiotensin receptor. Eur. J. Pharmacol. 257, 3178–3182.
Jones, K. A., Brostow, T., Tamm, J. A., Crong, D. A., Zhou, M. M., Mui, M., Yew, W. J., Johnson, M., Gaughan, C., Huang, L. T., Tang, C., Shott, G., Sall, A., Schol, J. D., Knaup, K. E., Nagarathnam, D., Noble, S. A., Branchek, T. A., and Gerald, C. (1998). GABARAP receptor function as a heteromeric subunit of the α1-adrenoceptor complex. Nature 396, 674–679.
Kapustian, K., Malischek, B., Schler, V., Haid, J., Frossel, W., Beck, P., Moharlich, J., Buchfeld, S., Kulik, A., Shimputa, R., Karchan, A., and Bettler, B. (1998). GABARAP receptor subtypes assemble into functional heteromeric complexes. Nature 396, 683–687.
Lee, F. J., Xue, P., Lei, X., Vukanic, B., Chen, Y., Wang, T., Yang, T. Y., Nimmikar, R., Ba, X. M., and Liu, F. (2002). Dual regulation of dopamine D1 receptor-protein-protein interactions with the dopamine β-arrestin-2 is expressed in human prostate tissue and mediates a binding partner of α1-adrenoceptors. World J. Surg. 39, 157–163.
Hunyady, L., Ber, B., Baló, T., and Catt, K. J. (1994). Identification of a sympathetic Site-Topoc locus that determines agonist-induced internalization of the α1B angiotensin receptor. Eur. J. Pharmacol. 257, 3178–3182.
Jones, K. A., Brostow, T., Tamm, J. A., Crong, D. A., Zhou, M. M., Mui, M., Yew, W. J., Johnson, M., Gaughan, C., Huang, L. T., Tang, C., Shott, G., Sall, A., Schol, J. D., Knaup, K. E., Nagarathnam, D., Noble, S. A., Branchek, T. A., and Gerald, C. (1998). GABARAP receptor function as a heteromeric subunit of the α1-adrenoceptor complex. Nature 396, 674–679.
Kapustian, K., Malischek, B., Schler, V., Haid, J., Frossel, W., Beck, P., Moharlich, J., Buchfeld, S., Kulik, A., Shimputa, R., Karchan, A., and Bettler, B. (1998). GABARAP receptor subtypes assemble into functional heteromeric complexes. Nature 396, 683–687.
Lee, F. J., Xue, P., Lei, X., Vukanic, B., Chen, Y., Wang, T., Yang, T. Y., Nimmikar, R., Ba, X. M., and Liu, F. (2002). Dual regulation of dopamine D1 receptor-protein-protein interactions with the dopamine β-arrestin-2 is expressed in human prostate tissue and mediates a binding partner of α1-adrenoceptors. World J. Surg. 39, 157–163.
Hunyady, L., Ber, B., Baló, T., and Catt, K. J. (1994). Identification of a sympathetic Site-Topoc locus that determines agonist-induced internalization of the α1B angiotensin receptor. Eur. J. Pharmacol. 257, 3178–3182.
Jones, K. A., Brostow, T., Tamm, J. A., Crong, D. A., Zhou, M. M., Mui, M., Yew, W. J., Johnson, M., Gaughan, C., Huang, L. T., Tang, C., Shott, G., Sall, A., Schol, J. D., Knaup, K. E., Nagarathnam, D., Noble, S. A., Branchek, T. A., and Gerald, C. (1998). GABARAP receptor function as a heteromeric subunit of the α1-adrenoceptor complex. Nature 396, 674–679.
Kapustian, K., Malischek, B., Schler, V., Haid, J., Frossel, W., Beck, P., Moharlich, J., Buchfeld, S., Kulik, A., Shimputa, R., Karchan, A., and Bettler, B. (1998). GABARAP receptor subtypes assemble into functional heteromeric complexes. Nature 396, 683–687.
Lee, F. J., Xue, P., Lei, X., Vukanic, B., Chen, Y., Wang, T., Yang, T. Y., Nimmikar, R., Ba, X. M., and Liu, F. (2002). Dual regulation of dopamine D1 receptor-protein-protein interactions with the dopamine β-arrestin-2 is expressed in human prostate tissue and mediates a binding partner of α1-adrenoceptors. World J. Surg. 39, 157–163.
Hunyady, L., Ber, B., Baló, T., and Catt, K. J. (1994). Identification of a sympathetic Site-Topoc locus that determines agonist-induced internalization of the α1B angiotensin receptor. Eur. J. Pharmacol. 257, 3178–3182.
Jones, K. A., Brostow, T., Tamm, J. A., Crong, D. A., Zhou, M. M., Mui, M., Yew, W. J., Johnson, M., Gaughan, C., Huang, L. T., Tang, C., Shott, G., Sall, A., Schol, J. D., Knaup, K. E., Nagarathnam, D., Noble, S. A., Branchek, T. A., and Gerald, C. (1998). GABARAP receptor function as a heteromeric subunit of the α1-adrenoceptor complex. Nature 396, 674–679.
Johnstone and Pfleger Application of receptor-HIT using BRET

receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells. Cell Signal 21, 428–439.

White, J. H., Wise, A., Main, M. J., Green, A., Emson, P., Foord, S. M., and Marshall, F. H. (1998). Heterodimerization is required for the formation of a functional GABA(B) receptor. Nature 396, 679–682.

Zhang, J. H., Chung, T. D., and Oldenburg, K. R. (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67–73.

Conflict of Interest Statement: In addition to being Head of the Laboratory for Molecular Endocrinology — GPCRs, Western Australian Institute for Medical Research and Centre for Medical Research, The University of Western Australia, Associate Professor Kevin D. G. Pfleger is Chief Scientific Officer of Dimerix Bioscience, a spin-out company of The University of Western Australia that has been assigned the rights to the ‘Receptor-HIT’ technology. Associate Professor Kevin D. G. Pfleger has a minor shareholding in Dimerix.

Received: 30 April 2012; accepted: 04 August 2012; published online: 22 August 2012.

Citation: Johnstone, EKM and Pfleger, KDG (2012) Receptor-Heteromer Investigation Technology and its application using BRET. Front. Endocrin. 3:101. doi: 10.3389/fendo.2012.00101

This article was submitted to Frontiers in Molecular and Structural Endocrinology, a specialty of Frontiers in Endocrinology.

Copyright © 2012 Johnstone and Pfleger. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and any copyright notices concerning any third-party graphics etc.